We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock

Delisted

SIOX was delisted on the 22nd of March, 2023.

81 hedge funds and large institutions have $323M invested in Sio Gene Therapies Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

147% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 15

94% more call options, than puts

Call options by funds: $535K | Put options by funds: $276K

16% more funds holding

Funds holding: 7081 (+11)

11% more capital invested

Capital invested by funds: $291M → $323M (+$32.2M)

Holders
81
Holders Change
+11
Holders Change %
+15.71%
% of All Funds
2.16%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.11%
New
16
Increased
37
Reduced
15
Closed
5
Calls
$535K
Puts
$276K
Net Calls
+$259K
Net Calls Change
+$168K

SIOX Hedge Fund Activity: Q2 2016 in Review

81 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2016, worth a combined $323M — up 11% from $291M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SIOX positions and 5 closed out — a net gain of 11 holders — while 37 added to existing stakes and 15 trimmed.

The largest buyer was Ziff Brothers Investments, opening a new position worth an estimated $12M. The largest seller was Visium Asset Management, cutting an estimated $52.2M.

  • 81 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2016, up from 70 in Q1 2016.
  • Funds reported $323M of Sio Gene Therapies Inc. Common Stock stock for Q2 2016, up 11% quarter-over-quarter.
  • 16 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2016 and 5 closed out, a net change of +11 holders.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2016 was Ziff Brothers Investments, an estimated $12M added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2016 was Visium Asset Management, an estimated $52.2M sold.

Based on aggregated 13F filings for Q2 2016.